68293-32-3

Usage

Uses

Used in Chemical Research and Development:
5-Methyl-7-hydroxy-1-indanone is used as a key intermediate in the synthesis of various organic compounds. Its unique structure allows it to be a valuable building block in the preparation of pharmaceuticals, agrochemicals, and other specialty chemicals. 5-Methyl-7-hydroxy-1-indanone's reactivity and stability make it an essential component in the development of new chemical entities and materials.
Used in Pharmaceutical Industry:
5-Methyl-7-hydroxy-1-indanone is used as a starting material for the synthesis of drug candidates. Its structural features enable the creation of novel molecules with potential therapeutic applications. Researchers in the pharmaceutical industry utilize 5-Methyl-7-hydroxy-1-indanone to explore its potential in the development of new drugs, particularly in areas such as pain management, anti-inflammatory agents, and other therapeutic areas.
Used in Agrochemical Industry:
5-Methyl-7-hydroxy-1-indanone is used as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its chemical properties make it suitable for the development of new active ingredients that can be used to control pests and weeds in agriculture. 5-Methyl-7-hydroxy-1-indanone's versatility in chemical reactions allows for the creation of innovative agrochemical products with improved efficacy and reduced environmental impact.
Used in Specialty Chemicals:
5-Methyl-7-hydroxy-1-indanone is used as a raw material in the production of specialty chemicals, such as fragrances, dyes, and coatings. Its unique chemical structure contributes to the development of new products with enhanced properties, such as improved stability, color, and scent. 5-Methyl-7-hydroxy-1-indanone's role in the synthesis of these specialty chemicals is crucial for meeting the diverse needs of various industries.

InChI:InChI=1/C10H10O2/c1-6-4-7-2-3-8(11)10(7)9(12)5-6/h4-5,12H,2-3H2,1H3

Upstream product

• 158304-80-4 3-methylphenyl β-chloropropionate 
• 68293-34-5 2-bromo-propionic acid m-tolyl ester 
• 173381-70-9 4-bromo-7-hydroxy-5-methylindan-1-one 
• 127766-76-1 3,5-dimethyl-4-bromophenol acetate 
• 173381-60-7 4-bromo-3-methylphenyl 3-chloropropionate 
• 173381-68-5 3-(2'-bromo-5'-hydroxy-3'-methylphenyl)propanoic acid 
• 173381-64-1 5-acetoxy-2-bromo-3-methylbenzyl bromide 
• 16108-50-2 1-(2-hydroxy-4,6-dimethylphenyl)ethanone 
• 1265683-79-1 2-(2-hydroxy-4,6-dimethylphenyl)-2-oxoethyl benzoate 
• 1265683-72-4 2-benzyloxy-4,6-dimethylacetophenone 
• 1265683-81-5 2-benzyloxy-4,6-dimethylphenacyl bromide 
• 1265683-82-6 2-benzyloxy-4,6-dimethylphenacyl benzoate 
• 877-82-7 5-acetoxy-m-xylene 
• 108-68-9 3,5-Dimethylphenol 

Downstream Products

• 20294-32-0 6-methyl-4-indanol 

Relevant academic research and scientific papers

The Discovery of (S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H -inden-4-yl)pyridin-2-yl)-5-methyl-1 H -pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma

Soluble guanylate cyclase (sGC), the endogenous receptor for nitric oxide (NO), has been implicated in several diseases associated with oxidative stress. In a pathological oxidative environment, the heme group of sGC can be oxidized becoming unresponsive to NO leading to a loss in the ability to catalyze the production of cGMP. Recently a dysfunctional sGC/NO/cGMP pathway has been implicated in contributing to elevated intraocular pressure associated with glaucoma. Herein we describe the discovery of molecules specifically designed for topical ocular administration, which can activate oxidized sGC restoring the ability to catalyze the production of cGMP. These efforts culminated in the identification of compound (+)-23, which robustly lowers intraocular pressure in a cynomolgus model of elevated intraocular pressure over 24 h after a single topical ocular drop and has been selected for clinical evaluation.

INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The power of solvent in altering the course of photorearrangements

A clean bifurcation between two important photochemical reactions through competition of a triplet state Type II H-abstraction reaction with a photo-Favorskii rearrangement for (o/p)-hydroxy-o-methylphenacyl esters that depends on the water content of the solvent has been established. The switch from the anhydrous Type II pathway that yields indanones to the aqueous-dependent pathway producing benzofuranones occurs abruptly at low water concentrations (～8%). The surprisingly clean yields suggest that such reactions are synthetically promising.

Anionic cyclizations of aromatic ester dithioacetals with facially biased α,β-unsaturated ketones

Cyclopent-2-enones bearing a plane-nonsymmetric oxygen function on C-4 reacted efficiently with anions derived from aromatic ester dithioacetals to provide annulated products in a highly diastereoselective fashion. Whereas the anion of a dimethoxy aromati

Synthesis of (±)-fredericamycin A

The synthesis of (±)-fredericamycin A (1) is reported with full experimental detail. Preparations of building blocks for the upper (2) and lower (3) units of 1 are described. The union of 2 and 3 by a two-step 1,4-dipolar cycloaddition and the elaboration